Several studies investigated the correlation between EGLN2 4-bp ins/del polymorphism (rs10680577) and susceptibility to various cancer comprising breast cancer (Hashemi et al., 2018b), colorectal cancer (Li et al., 2017), gastric cancer (Wang et al., 2014), hepatocellular carcinoma (HCC) (Zhu et al., 2012), and lung cancer (Che et al., 2014; Zhu et al., 2018), As far as we know, there is no data concerning the impact of EGLN2 4-bp ins/del polymorphism on PCa susceptibility. This evidence concerns the gene EGLN2 and lung cancer.